Tags

Type your tag names separated by a space and hit enter

Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.
PLoS One. 2012; 7(10):e48171.Plos

Abstract

OBJECTIVE

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is deemed to play a role in atherosclerosis and plaque destabilization as demonstrated in animal models and in prospective clinical studies. However, most of the literature is either focused on high-risk, apparently healthy patients, or is based on cross sectional studies. Therefore, we tested the hypothesis that serum Lp-PLA2 mass and activity are useful for predicting cardiovascular (CV) events over the coronary atherosclerotic burden and conventional risk factors in high-risk coronary artery disease patients.

METHODS AND RESULTS

In a prospective cohort study of 712 Caucasian patients, who underwent coronary angiography and measurement of both Lp-PLA2 mass and activity at baseline, we determined incident CV events at follow-up after splitting the patients into a high and a low Lp-PLA2 mass and activity groups based on ROC analysis and Youden index. Kaplan-Meier and propensity score matching analysis were used to compare CV event-free survival between groups. Follow-up data were obtained in 75% of the cohort after a median of 7.2 years (range 1-12.7 years) during which 129 (25.5%) CV events were observed. The high Lp-PLA2 activity patients showed worse CV event-free survival (66.7% vs. 79.5%, p = 0.023) and acute coronary syndrome-free survival (75.4% vs. 85.6%, p = 0.04) than those in low Lp-PLA2 group.

CONCLUSIONS

A high Lp-PLA2 activity implies a worse CV prognosis at long term follow up in high-risk Caucasian patients referred for coronary angiography.

Authors+Show Affiliations

Department of Medicine, Internal Medicine 4, University of Padua, Padua, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23118945

Citation

Maiolino, Giuseppe, et al. "Lipoprotein-associated Phospholipase A2 Activity Predicts Cardiovascular Events in High Risk Coronary Artery Disease Patients." PloS One, vol. 7, no. 10, 2012, pp. e48171.
Maiolino G, Pedon L, Cesari M, et al. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PLoS ONE. 2012;7(10):e48171.
Maiolino, G., Pedon, L., Cesari, M., Frigo, A. C., Wolfert, R. L., Barisa, M., Pagliani, L., Rossitto, G., Seccia, T. M., Zanchetta, M., & Rossi, G. P. (2012). Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PloS One, 7(10), e48171. https://doi.org/10.1371/journal.pone.0048171
Maiolino G, et al. Lipoprotein-associated Phospholipase A2 Activity Predicts Cardiovascular Events in High Risk Coronary Artery Disease Patients. PLoS ONE. 2012;7(10):e48171. PubMed PMID: 23118945.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. AU - Maiolino,Giuseppe, AU - Pedon,Luigi, AU - Cesari,Maurizio, AU - Frigo,Anna Chiara, AU - Wolfert,Robert L, AU - Barisa,Marlena, AU - Pagliani,Leopoldo, AU - Rossitto,Giacomo, AU - Seccia,Teresa Maria, AU - Zanchetta,Mario, AU - Rossi,Gian Paolo, Y1 - 2012/10/31/ PY - 2012/08/08/received PY - 2012/09/21/accepted PY - 2012/11/3/entrez PY - 2012/11/3/pubmed PY - 2013/4/16/medline SP - e48171 EP - e48171 JF - PloS one JO - PLoS ONE VL - 7 IS - 10 N2 - OBJECTIVE: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is deemed to play a role in atherosclerosis and plaque destabilization as demonstrated in animal models and in prospective clinical studies. However, most of the literature is either focused on high-risk, apparently healthy patients, or is based on cross sectional studies. Therefore, we tested the hypothesis that serum Lp-PLA2 mass and activity are useful for predicting cardiovascular (CV) events over the coronary atherosclerotic burden and conventional risk factors in high-risk coronary artery disease patients. METHODS AND RESULTS: In a prospective cohort study of 712 Caucasian patients, who underwent coronary angiography and measurement of both Lp-PLA2 mass and activity at baseline, we determined incident CV events at follow-up after splitting the patients into a high and a low Lp-PLA2 mass and activity groups based on ROC analysis and Youden index. Kaplan-Meier and propensity score matching analysis were used to compare CV event-free survival between groups. Follow-up data were obtained in 75% of the cohort after a median of 7.2 years (range 1-12.7 years) during which 129 (25.5%) CV events were observed. The high Lp-PLA2 activity patients showed worse CV event-free survival (66.7% vs. 79.5%, p = 0.023) and acute coronary syndrome-free survival (75.4% vs. 85.6%, p = 0.04) than those in low Lp-PLA2 group. CONCLUSIONS: A high Lp-PLA2 activity implies a worse CV prognosis at long term follow up in high-risk Caucasian patients referred for coronary angiography. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/23118945/Lipoprotein_associated_phospholipase_A2_activity_predicts_cardiovascular_events_in_high_risk_coronary_artery_disease_patients_ L2 - http://dx.plos.org/10.1371/journal.pone.0048171 DB - PRIME DP - Unbound Medicine ER -